The irony here is that of the 4 TCGA GBM subtypes - mesenchymal is the worst of the worst subtype - meaning chances of survival are -0- - yet DCVax-L worked best within that subtype
Liau and Prins commented on this in a 2011 paper(s) of theirs I don't have the links
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278117/ Microarray gene-expression profiling revealed that Jones and the others in his trial who are still alive had tumors with mesenchymal gene-expression signatures. In the Prins study, an analysis of tumor tissue with a mesenchymal gene-expression signature showed that these tumors have a higher number of CD3+ and CD8+ tumor-infiltrating lymphocytes compared with glioblastomas with other gene-expression signatures. The authors theorized that “the mesenchymal gene-expression profile may identify an immunogenic subgroup of glioblastoma that may be more responsive to immune-based therapies.”